CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
10.03
close · 2026-10-30
value
92
cheaper than peers92
quality
93
stronger fundamentals93
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -5.6% | 87 |
| earnings yield, latest year | -5.3% | 87 |
| cash flow yield, latest year | -3.9% | 84 |
| cash flow yield, 2 years ago | -2.8% | 83 |
| cash flow yield, 1 year ago | -3.0% | 81 |
| earnings yield, 3 years ago | -8.9% | 75 |
| cash flow yield, 3 years ago | -3.2% | 75 |
| earnings yield, 1 year ago | -10.2% | 70 |
| price to book | 3.74× | 37 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.3% | 88 |
| return on equity | -30.5% | 87 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $844M |
| free cash flow | -$22.6M |
| employees | 37 |
| first trade | 2016-03-23 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.53 | -1.02 | -0.56 | -0.89 |
| free cash flow | -$33.0M | -$25.4M | -$24.0M | -$27.3M |
| net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $27.1M | -$33.4M | $0 | $22,000 |